Sun Pharma Starts Phytopharmaceutical Dengue Drug Trial for COVID-19, an Industrial Info Market Brief

---

Indian pharma-giant Sun Pharmaceutical Industries Limited announced that it has commenced Phase II clinical trials on AQCH, a phytopharmaceutical experimental drug for treatment of COVID-19. The company has already received approval from the Drugs Controller General of India (DCGI) for conducting the trial.

The drug, which is being developed for treatment of dengue fever, has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy and hence is being tested as a potential treatment option for COVID-19.

"The clinical trial will be conducted across 12 centers in India on 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trial are expected by October 2020," said a Sun Pharma media release. Industrial Info is tracking 13 Sun Pharm projects worth $ 117.71 million in India. Click here for a list and see map below.